Antimicrobials
DAPTOmycin

DAPTOmycin

Restricted

Low
N/A
$$

Spectrum of Activity

General Information

Bacteremia caused by methicillin resistant S. aureus with intermediate susceptibility to vancomycin (MIC≥ 2mcg/mL).

Should NOT be used for the treatment of bacteremia associated with pneumonia or central nervous infection.

Creatine kinase weekly.

  • GI side effects common

  • Rash

  • Phlebitis

  • Increased INR

  • Myopathy including rhabdomyolysis

Statins and fibrates - Increased myopathy.

Monitor creatine kinase or hold while on daptomycin therapy.

Higher doses used for endovascular infection.

Recommend Infectious Disease Consult.

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

For outpatient funding, Patient must meet ODB EAP criteria (See criteria by clicking on this link: Telephone Request Service EAP Criteria (gov.on.ca)). 

Please call ODB Telephone Request Service (1-866-811-9893) to get Exceptional Access Program approval for ODB outpatients.

Antimicrobial class: Cyclic Lipopeptide

Pregnancy category: B

Average serum half life: 9 hours

CSF penetration: Poor

Lung penetration: Poor

Urine penetration: Therapeutic